135 related articles for article (PubMed ID: 17013817)
21. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
22. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
[TBL] [Abstract][Full Text] [Related]
23. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
Zinzani PL; Alinari L; Tani M; Fina M; Pileri S; Baccarani M
Haematologica; 2005 May; 90(5):702-3. PubMed ID: 15921394
[TBL] [Abstract][Full Text] [Related]
24. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.
Matsunaga T; Sakamaki S; Ishigaki S; Kohda K; Takeda M; Katoh J; Kuroda H; Hirayama Y; Kusakabe T; Akiyama T; Kuga T; Niitsu Y; Masaoka T; Sagawa T; Matsumoto Y
Int J Hematol; 1999 Feb; 69(2):105-11. PubMed ID: 10071460
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
26. Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy.
Kuo CP; Wu CL; Ho HT; Chen CG; Liu SI; Lu YT
Clin Microbiol Infect; 2008 Mar; 14(3):221-7. PubMed ID: 18070129
[TBL] [Abstract][Full Text] [Related]
27. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
28. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
Kline J; Pollyea DA; Stock W; Artz A; Rich E; Godley L; Zimmerman T; Thompson K; Pursell K; Larson RA; van Besien K
Bone Marrow Transplant; 2006 Feb; 37(3):307-10. PubMed ID: 16400339
[TBL] [Abstract][Full Text] [Related]
29. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.
Siegal D; Xu W; Sutherland R; Kamel-Reid S; Kuruvilla J; Lipton JH; Minden M; Messner H; Gupta V
Bone Marrow Transplant; 2008 Jul; 42(1):51-6. PubMed ID: 18372907
[TBL] [Abstract][Full Text] [Related]
30. [Investigation of cytomegalovirus positivity in the peripheral blood samples of risky patients by shell-vial cell culture, antigenemia test and real-time polymerase chain reaction].
Gökahmetoğlu S; Yağmur G; Mutlu Sarıgüzel F; Deniz E
Mikrobiyol Bul; 2011 Apr; 45(2):288-95. PubMed ID: 21644072
[TBL] [Abstract][Full Text] [Related]
31. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
O'Brien S; Ravandi F; Riehl T; Wierda W; Huang X; Tarrand J; O'Neal B; Kantarjian H; Keating M
Blood; 2008 Feb; 111(4):1816-9. PubMed ID: 18039954
[TBL] [Abstract][Full Text] [Related]
32. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients.
Matsuoka K; Iwao Y; Mori T; Sakuraba A; Yajima T; Hisamatsu T; Okamoto S; Morohoshi Y; Izumiya M; Ichikawa H; Sato T; Inoue N; Ogata H; Hibi T
Am J Gastroenterol; 2007 Feb; 102(2):331-7. PubMed ID: 17156136
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
[TBL] [Abstract][Full Text] [Related]
35. [Prognosis value of the pp65 antigenemia and semi-quantitative PCR in the detection of the CMV reactivation in bone marrow grafted patients].
Ksouri H; Lakhal A; Ben Amor R; Torjman L; Achour W; Ben Othmen T; Ladeb S; Abdelkefi A; Slim A; Abdeladhim A; Ben Hassen A
Bull Soc Pathol Exot; 2006 Jul; 99(3):155-9. PubMed ID: 16983816
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.
Cortez KJ; Fischer SH; Fahle GA; Calhoun LB; Childs RW; Barrett AJ; Bennett JE
J Infect Dis; 2003 Oct; 188(7):967-72. PubMed ID: 14513415
[TBL] [Abstract][Full Text] [Related]
37. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Yang DH; Lee JJ; Kim YK; Kim HJ; Shin HJ; Chung JS; Cho GJ
Am J Hematol; 2008 Aug; 83(8):649-53. PubMed ID: 18528826
[TBL] [Abstract][Full Text] [Related]
38. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
39. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Chakrabarti S; Mackinnon S; Chopra R; Kottaridis PD; Peggs K; O'Gorman P; Chakraverty R; Marshall T; Osman H; Mahendra P; Craddock C; Waldmann H; Hale G; Fegan CD; Yong K; Goldstone AH; Linch DC; Milligan DW
Blood; 2002 Jun; 99(12):4357-63. PubMed ID: 12036862
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of cytomegaloviral antigenemia test and re-test after antiviral chemotherapy in patients with autoimmune and non-autoimmune diseases].
Cui JT; Ni AP; Wu YL; Kong LJ; Yan WJ; Li Q; Dou YL; Chen LL
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(34):2426-9. PubMed ID: 23158667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
